

## Otto Buttula to revert back to Non-Executive Chair

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”), whose initial mission is to deliver a test to detect Colorectal Cancer early, announces that in line with previous market announcements, Mr Otto Buttula will revert to a non-executive position, formally relinquishing all executive duties, effective 31 May 2024.

This follows the commencement of Dr David Atkins as Chief Executive Officer on 13 May 2024. Dr David Atkins is an accomplished global healthcare leader and has already assumed day-to-day executive leadership, with all material handover activities expected to be completed by the end of the month.

Mr Otto Buttula will continue as Non-Executive Chairman, making himself available to support the chief executive and team as required.

The Board thanks Mr Buttula for his additional commitment during his executive tenure.

- ENDS -

### Authorisation & Additional Information

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.  
For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com)**

<b>Dr David Atkins</b> Chief Executive Officer	<b>Andrea Steele</b> General Counsel & Joint Company Secretary
---	---

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable. The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**T** +61 3 8256 2880  
**E** [info@rhythmbio.com](mailto:info@rhythmbio.com)

David Atkins  
**Directors**  
Otto Buttula  
Sue MacLeman

Trevor Lockett  
Louis Panaccio

Chief Executive Officer

Executive Chairman  
Non-Executive Independent  
Deputy Chair  
Non-Executive Director  
Non-Executive Director